Future Directions in Therapies for Acute Respiratory Distress Syndrome.
ARDS
Inflammation
Phenotype
Treatment
Journal
Clinics in chest medicine
ISSN: 1557-8216
Titre abrégé: Clin Chest Med
Pays: United States
ID NLM: 7907612
Informations de publication
Date de publication:
Dec 2024
Dec 2024
Historique:
medline:
24
10
2024
pubmed:
24
10
2024
entrez:
23
10
2024
Statut:
ppublish
Résumé
Acute respiratory distress syndrome (ARDS) is caused by a complex interplay among hyperinflammation, endothelial dysfunction, and alveolar epithelial injury. Targeted treatments toward the underlying pathways have been unsuccessful in unselected patient populations. The first reliable biological subphenotypes reflective of these biological disease states have been identified in the past decade. Subphenotype targeted intervention studies are needed to advance the pharmacologic treatment of ARDS.
Identifiants
pubmed: 39443010
pii: S0272-5231(24)00076-5
doi: 10.1016/j.ccm.2024.08.014
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
943-951Informations de copyright
Copyright © 2024 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Disclosure L. D.J. Bos reports funding from Health Holland, Longfonds, ZonMw, Innovative Medicine Initiative and has consulted for Astra Zeneca, Pfizer, Sobi, Novartis, CSL Behring, Scailyte, and Santhera. All financial contributions were paid to the institution. J.E. Millar and K. Reddy declare no COI.